09/29/2026
I want to talk about why the vaccine question matters when it comes to Zenrelia, and how to think of it for patients like yours.
This week, a few of my patients were taken off Zenrelia for vaccination purposes. I understand why, that's what the label says. But, I still hear a lot of actual concern around this.
That fear comes from somewhere, and I want to address it.
Zenrelia (ilunocitinib) is a JAK inhibitor, FDA-approved as a once-daily oral tablet for control of pruritus and atopic dermatitis in dogs 12 months and older. It carries a boxed warning, the FDA's strongest safety alert. At launch in 2024, that warning was for fatal vaccine-induced disease and inadequate immune response to vaccines.
The dogs in that original study were purpose-bred beagles, about 10 months old, vaccine-naive, dosed at up to three times the label dose, and undergoing their first-ever vaccine series while on the drug. While in the study, their facility had two infectious disease outbreaks, coccidiosis and canine adenovirus. The dogs in the lab (the lab that is supposed to be clean and research-oriented) got sick, and two were euthanized due to declining health. The study carried on anyway. This is not normal. And this is not what we typically have in front of us when we're deciding whether to treat a patient's allergic symptoms.
Allergic dogs are usually otherwise healthy, not fighting infectious hepatitis and severe diarrhea at the same time while receiving 3x Zenrelia and their first core vaccines ever.
In Sept 2025, the FDA actually did act: they removed the fatal-disease language from the label after determining the deaths were tied to natural CAV-1 infection during that outbreak, not the drug itself. What remains on the label is the immune-response caution and the 28-day-to-3-month discontinuation window around vaccination.
So why does the immune-response caution still matter, and what does the data say?
Vaccines exist to give protective immunity for future exposure. The real question: does this drug blunt that response in dogs who are actually being vaccinated the way most of our patients are - already vaccinated, getting a routine booster?
A second 2025 study answered this. Dogs previously vaccinated under standard protocol, even at 3x the label dose, mounted normal, protective antibody responses to rabies, adenovirus, distemper, and parvo on booster (Fent et al., 2025, BMC Vet Res).
That's the study that actually maps onto how most of us use this drug clinically, a booster in an already-vaccinated dog, not a first-ever vaccine series in a naive dog.
We have the ability to make individualized patient decisions. In no way is this post establishing VCPR or giving medical advice. But, I hope it helps you.
